Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of barzolvolimab in chronic spontaneous urticaria
2021-006413-11Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of barzolvolimab in chronic idiopathic urticaria (CIU) (4 arms), sponsored by Celldex Therapeutics. Primary endpoint: Mean change from baseline to Week 12 in UAS7. Started Apr 2022; status: completed.
02
Drugs
barzolvolimab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2021-006413-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006413-11.